If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-01. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
== First published posthumously == De Profundis (written 1895–97, in Reading Gaol). Expurgated edition published 1905; suppressed portions 1913, expanded version in The Letters of Oscar Wilde (1962). The Rise of Historical Criticism (written while at college). First published in 1905 (Sherwood Press, Hartford, CT), privately printed. Reprinted in Miscellanies, the last volume of the First Collected Edition (1908). The First Collected Edition (Methuen & Co., 14 volumes) appeared in 1908 and contained many previously unpublished works. The Second Collected Edition (Methuen & Co., 12 volumes) appeared in installments between 1909–11 and contained several other unpublished works. The Letters of Oscar Wilde (written 1868–1900). Published in 1962. Republished as The Complete Letters of Oscar Wilde (2000), with letters discovered since 1962 and new annotations by Merlin Holland. The Women of Homer (written 1876, while at college). First published in Oscar Wilde: The Women of Homer (2008) by the Oscar Wilde Society.
We were of course glad to meet again and became close friends. On my side feelings developed gradually over the next two years. He seemed to have made his mind up much more quickly, however, and became even more keen when, in the autumn of 1910, rumours spread about that I had got engaged to a distant Spanish relative, Don Jaime, the Duke of Madrid. On hearing this, the Archduke came down post haste from his regiment at Brandýs and sought out his grandmother, Archduchess Maria Theresa, who was also my aunt and the natural confidante in such matters. He asked if the rumor was true and when told it was not, he replied, "Well, I had better hurry in any case or she will get engaged to someone else." Archduke Charles traveled to Villa Pianore and asked for Zita's hand and, on 13 June 1911, their engagement was announced at the Austrian court. Zita in later years recalled that after her engagement she had expressed to Charles her worries about the fate of the Austrian Empire and the challenges of the monarchy. Charles and Zita were married at the Schwarzau castle on 21 October 1911. Charles's great-uncle, the 81-year-old Emperor Franz Joseph I, attended the wedding. He was relieved to see an heir make a suitable marriage, and was in good spirits, even leading the toast at the wedding breakfast. Archduchess Zita soon conceived a son, and Otto was born on 20 November 1912. Seven more children followed in the next decade.
== Uses == Industrially, anthranilic acid is an intermediate in the production of azo dyes (c.f. methyl red) and saccharin. It and its esters are used in preparing perfumes to mimic jasmine and orange, pharmaceuticals (loop diuretics, such as furosemide) and UV-absorber as well as corrosion inhibitors for metals and mold inhibitors in soy sauce. Anthranilate-based insect repellents have been proposed as replacements for DEET. Fenamic acid is a derivative of anthranilic acid, which in turn is a nitrogen isostere of salicylic acid, which is the active metabolite of aspirin. Several non-steroidal anti-inflammatory drugs, including mefenamic acid, tolfenamic acid, flufenamic acid, and meclofenamic acid are derived from fenamic acid or anthranilic acid and are called "anthranilic acid derivatives" or "fenamates". Anthranilic acid [118-92-3] was demonstrated to have utility in the synthesis of the following list of substances: clozapine, quetiapine, thiosalicylic acid, ofornine, strinoline, ciliobrevin A, bentazon, quinezamide, nifurquinazol, nitromethaqualone, & YT-1 (1-azaflavone) [14802-18-7], atolide (actually isatoic anhydride), melicopicine. & tranilast. U-17660 [13450-72-1] & THA-Q [4425-23-4].
Sources: en.wikipedia.org
=== Chief executives === 1907–1962, James E. "Jim" Casey 1962–1972, George D. Smith 1972–1973, Paul Oberkotter 1973–1980, Harold Oberkotter 1980–1984, George Lamb 1984–1989, John W. Rogers 1989–1996, Kent C. "Oz" Nelson 1997–2001, James P. Kelly 2002–2007, Michael L. "Mike" Eskew 2008–2014, Scott Davis 2014–2020, David Abney 2020–current, Carol B. Tomé
== Background == Even before the beginning of the war, the Mexican government showed its disapproval of fascist nations on multiple occasions. On November 6, 1935, Mexico joined the League of Nations economic blockades against the Kingdom of Italy for the invasion and subsequent annexation of the Ethiopian Empire. A few years later, on March 19, 1938, Mexico protested before the League of Nations against the violation of Austrian sovereignty after the Anschluss, whereas the United Kingdom, France, and the United States remained silent. The most famous case of Mexico's rejection of fascism was the recognition of the Spanish Republican government in exile. On June 17, 1939, the Mexican government withdrew its embassy from Spanish territory, leaving diplomatic affairs in the hands of the Cuban embassy. Since 1937, Spanish refugees (notably Republican supporters) had been arriving on Mexican shores and were received by the authorities in the Port of Veracruz, where ships loaded with Spaniards and some Jews persecuted in Europe by the Nazis arrived. During this period, Mexico's diplomatic relations with democratic nations were strained. Since the oil expropriation of 1938, the United Kingdom had broken off relations, and the United States maintained a commercial blockade against Mexico. In addition, the Soviet Union had withdrawn its ambassador since the Cardenista government gave political asylum to Leon Trotsky, who was a strong opponent of Joseph Stalin's regime.
Lipedema is a chronic medical condition that is almost exclusively found in women and results in enlargement of both legs due to deposits of fat under the skin. It is characterized by bilateral, symmetrical buildup of fat in the legs, and sometimes arms and lower trunk (includes hips, buttocks, and abdomen). Women of any weight may be affected and the fat is resistant to traditional weight-loss methods like nutritional intervention, exercise, elevation, diuretics or bariatric surgery. The feet/hands are typically spared, presenting with a raised ridge or fold of fat, possibly a "cuff" at the wrists and ankles. In earlier stages, there may be a subtle, raised ridge or fold of fat instead of distinct cuffing and sometimes in the later stages, this increased adipose above the ankle/wrist can cause the appearance of a "cuff". Approximately 50% of people with Lipedema report pain in their fat. Other common symptoms include swelling, feelings of heaviness, and easy bruising in the affected areas. Over time mobility may be reduced, and due to reduced quality of life, people often experience depression. The cause is unknown but is believed to involve genetic and hormonal factors, lipedema onset is typically associated with periods of hormonal flux like puberty, pregnancy, or menopause and it often runs in families. Other conditions that may present similarly include lipohypertrophy, chronic venous insufficiency, and lymphedema. It is commonly misdiagnosed.
The harvesting, processing, and consuming of seafoods are ancient practices with archaeological evidence dating back well into the Paleolithic. Findings in a sea cave at Pinnacle Point in South Africa indicate Homo sapiens (modern humans) harvested marine life as early as 165,000 years ago, while the Neanderthals, an extinct human species contemporary with early Homo sapiens, appear to have been eating seafood at sites along the Mediterranean coast beginning around the same time. Isotopic analysis of the skeletal remains of Tianyuan man, a 40,000-year-old anatomically modern human from eastern Asia, has shown that he regularly consumed freshwater fish. Archaeology features such as shell middens, discarded fish bones, and cave paintings show that sea foods were important for survival and consumed in significant quantities. During this period, most people lived a hunter-gatherer lifestyle and were, of necessity, constantly on the move. However, early examples of permanent settlements (though not necessarily permanently occupied), such as those at Lepenski Vir, were almost always associated with fishing as a major source of food. The ancient river Nile was full of fish; fresh and dried fish were a staple food for much of the population. The Egyptians had implements and methods for fishing and these are illustrated in tomb scenes, drawings, and papyrus documents. Some representations hint at fishing being pursued as a pastime.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.